Investor Presentaiton
•
Highlights of additional MRD studies underway
INVESTOR 20
DAY 23
Near-term readouts
Breast Cancer
Clinical Validity Study
•
Post-adjuvant chemoRx cohort
Submitted to San Antonio Breast
Cancer Symposium (SABCS)
> 300 early breast cancer
patients across all subtypes
•
Median follow-up of 66 months
•
GUARDANT™
PEGASUS
De-Escalation Clinical Utility Trial
(Standard of Care Chemotherapy) CRC
Long-term readouts
TRACC Part C
De-Escalation Clinical Utility Trial
(Standard of Care Chemotherapy) CRC
•
•
Ph II single-arm study
Ph III randomized control trial
•
Data readout submitted to ESMO
•
Study enrollment ongoing
140 high-risk stage II & stage III
colon cancer patients after
surgical resection
Study fully enrolled in 2022.
•
•
1621 high-risk stage II & stage III
colon cancer patients after
surgical resection
Expect to complete enrollment in
early 2027
69
69View entire presentation